GW Pharmaceuticals cannabinoid for cancer pain likely to have encouraging US market penetration, abuse possibility uncertain – experts
http://ctcaho.pe/1lfsPUe
Although approval is limited to cancer related pain, Sativex should be made widely available due to a relatively low abuse potential for patients who don't get enough relief from opioids alone.
As a Marinol/dronabinol user, I'm excited about the possibility of a cannabinoid product without the intense high and unpredictable absorption of oral THC (Marinol). I can also verify the article's assertion that cannabinoids alone are inferior to cannabinoids added to to opioids.
I'm not sure if I'm the only one, but I'm extremely excited for this new, non-opioid (& opioid boosting) pain medication. I also find reports like this one reassuring, and a little exciting (I'm sure it's no big deal for patients in medical cannabis states, but it's important for those of us in Republican hell states, we have no cannabis, no Medicaid expansion, and we're desperate for a decent cannabinoid (oral dronabinol is terrible & the Marinol inhaler is stuck in clinical trials)).
Steve
